



SciGen To Consider Dual Listing in the Zurich Stock Exchange

25th June 2008: SciGen Limited (ASX:SIE) SciGen is actively exploring the possibility of a dual listing in the Zurich Stock Exchange. SciGen is considering this option as the Company enters into an exciting new phase of its development with its Hepatitis B Vaccine entering the market in four countries this calendar year and several more during next year.

A successful Dual Listing in the Zurich Stock Exchange, which is one of the strongest markets for emerging Biotechnology companies, will give SciGen the ability to fast track the development of Biosimilars in its pipeline, such as GCSF and at the same time have the necessary resources and funding to launch its third generation vaccine in major markets within the next three years.

About SciGen:

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and Biosimilar products, which allow for faster entry into the market, as Biosimilar products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in clinical development, gaining regulatory approval and bringing products to market.

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with subsidiary companies in the USA, Australia, S. Korea, Hong Kong, Philippines, Vietnam, Israel and India, a Joint Venture in China, commercial partners in Europe and collaborative partners in the USA and the Netherlands.

Further information:

Company – Investor Relations	Company
Ms. Gillian Dunlop SciGen Australia +61 2 9485 1800 email: gdunlop@scigen.com.au	Saul Mashaal Chairman, Founder & CEO SciGen Ltd. + 61 2 9485 1800 +65 9630 5691 (Mobile)